Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IdeaSphere markets Weil

This article was originally published in The Tan Sheet

Executive Summary

IdeaSphere will "assume exclusive, worldwide licensing rights" to Weil Nutritional Supplements, the New York-based firm announced Jan. 17. The product line, which was launched in March by author Andrew Weil, MD, currently is sold through Weil's website and in specialty health stores such as Whole Foods, GNC and Vitamin Shoppe. IdeaSphere will take over retail and direct marketing of the supplement line including online sales, the company states. IdeaSphere purchased Twinlab in 2003 and most recently completed the acquisition of Metabolife's non-ephedra brands including Metabolife Ultra in November (1"The Tan Sheet" Sept. 1, 2003, p. 3 and 2"The Tan Sheet" Nov. 14, 2005, In Brief)...

You may also be interested in...



Twinlab Finds Potential Buyer In IdeaSphere: End Of Blechman Era?

The proposed acquisition of Twinlab by nutritional products seller IdeaSphere would mark the end of the Blechman family ownership of the company, in place since the company's founding 35 years ago

Cipla's Advair Generic Debut In Sight, More Platform Deals On Radar Post Ethris

Cipla believes it is “pretty close” to approval for its Advair generic in the US, while another product, generic Abraxane, stands delayed currently. Following the deal with Ethris, which is progressing inhaled mRNA-based therapies, the company signals interest in platforms such as CAR-T as well.

Inside US FDA’s Return To In-Person Meetings

In an interview, OND Deputy Director of Operations Kevin Bugin describes how FDA might be able to "accelerate" the transition back to in-person meetings if the initial phase with Type A and BPD Type 1 meetings goes well. But there is still no plan to return to in-person advisory committees.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099026

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel